{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:50:05Z","timestamp":1791409805728,"version":"4.3.3"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacl.2026.09.016","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:26:11Z","timestamp":1790699171000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["NST-1024 for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 28-day clinical trial"],"prefix":"10.1016","author":[{"given":"John JP","family":"Kastelein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1347-2694","authenticated-orcid":false,"given":"Tore","family":"Skj\u00e6ret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Jeannin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8699-4549","authenticated-orcid":false,"given":"Robin","family":"Beyusen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7556-4351","authenticated-orcid":false,"given":"David A.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5147-5469","authenticated-orcid":false,"given":"Kevin C.","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jacl.2026.09.016_bib1","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.amjcard.2010.11.008","article-title":"Prevalence of severe (500\u20132,000 mg\/dl) hypertriglyceridemia in United States adults","volume":"107","author":"Christian","year":"2011","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.016_bib2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.jacl.2026.09.016_bib3","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects and treatment","volume":"176","author":"Yuan","year":"2007","journal-title":"CMAJ"},{"issue":"9","key":"10.1016\/j.jacl.2026.09.016_bib4","doi-asserted-by":"crossref","first-page":"626","DOI":"10.7326\/M19-0203","article-title":"The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment","volume":"170","author":"Chait","year":"2019","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.016_bib5","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-021-01488-8","article-title":"The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis","volume":"20","author":"Sanchez","year":"2021","journal-title":"Lipids Health Dis"},{"issue":"2","key":"10.1016\/j.jacl.2026.09.016_bib6","article-title":"Current and emerging treatment options for hypertriglyceridemia: state-of-the-art review","volume":"18","author":"Zimodro","year":"2025","journal-title":"Pharm (Basel)"},{"key":"10.1016\/j.jacl.2026.09.016_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2025.101356","article-title":"Temporal patterns of triglyceride testing and test results among adults with severe or extreme hypertriglyceridemia in US clinical practice","volume":"24","author":"Sikora Kessler","year":"2025","journal-title":"Am J Prev Cardiol"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.016_bib8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa2512761","article-title":"Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk","volume":"394","author":"Marston","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.09.016_bib9","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"9","key":"10.1016\/j.jacl.2026.09.016_bib10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1089\/met.2024.0093","article-title":"Severe hypertriglyceridemia in patients with type 2 diabetes mellitus participating in the AMD annals initiative","volume":"22","author":"Russo","year":"2024","journal-title":"Metab Syndr Relat Disord"},{"issue":"9","key":"10.1016\/j.jacl.2026.09.016_bib11","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1073\/pnas.94.9.4318","article-title":"Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma","volume":"94","author":"Kliewer","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.jacl.2026.09.016_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041763","article-title":"Pharmacology of free fatty acid receptors and their allosteric modulators","volume":"22","author":"Grundmann","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.jacl.2026.09.016_bib13","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1080\/13543784.2022.2159804","article-title":"Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH","volume":"31","author":"Fraser","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jacl.2026.09.016_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/lipd.12351","article-title":"Structurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease","volume":"57","author":"Secor","year":"2022","journal-title":"Lipids"},{"issue":"7","key":"10.1016\/j.jacl.2026.09.016_bib15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.016_bib16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am J Cardiol"},{"issue":"4-5","key":"10.1016\/j.jacl.2026.09.016_bib17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/lipd.12351","article-title":"Structurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease","volume":"57","author":"Secor","year":"2022","journal-title":"Lipids"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.016_bib18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jacl.2015.10.012","article-title":"Icosabutate for the treatment of very high triglycerides: a placebo-controlled, randomized, double-blind, 12-week clinical trial","volume":"10","author":"Bays","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"7","key":"10.1016\/j.jacl.2026.09.016_bib19","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","article-title":"The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jacl.2026.09.016_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175672","article-title":"Effects of statin therapy on glycemic control and insulin resistance: a systematic review and meta-analysis","volume":"947","author":"Alvarez-Jimenez","year":"2023","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"10.1016\/j.jacl.2026.09.016_bib21","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/dme.12159","article-title":"The clinical utility of C-peptide measurement in the care of patients with diabetes","volume":"30","author":"Jones","year":"2013","journal-title":"Diabet Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426005301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426005301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:00:13Z","timestamp":1791406813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426005301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":21,"alternative-id":["S1933287426005301"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.09.016","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NST-1024 for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 28-day clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}